Growth & profitability
- Revenue has declined 2.0% per year over the past 5 years.
- Operating margin has expanded, at -239.8% in the latest year.
CYCN Financials Cyclerion Therapeutics, Inc.
8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$4M | 0.0% | -239.8% | — | — | $3M |
| 2024 | $2M | -$3M | 0.0% | -181.4% | — | — | $3M |
| 2023 | $0 | -$5M | — | — | — | — | $8M |
| 2022 | $297000 | -$44M | 0.0% | -6242.4% | -$41M | — | $13M |
| 2021 | $4M | -$52M | 0.0% | -1400.2% | -$37M | — | $54M |
| 2020 | $2M | -$78M | 0.0% | -3539.4% | -$74M | — | $54M |
| 2019 | — | -$123M | — | — | -$109M | — | $95M |
| 2018 | — | -$115M | — | — | -$101M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$3M | — | — | -$1M | — | $3M |
| Dec '25 | $1M | -$799000 | 0.0% | -81.8% | — | — | $3M |
| Sep '25 | $875000 | -$976000 | 0.0% | -115.0% | — | — | $5M |
| Jun '25 | $93000 | -$324000 | 0.0% | -1797.8% | — | — | $3M |
| Mar '25 | $81000 | -$1M | 0.0% | -1798.8% | -$968000 | — | $4M |
| Dec '24 | $2M | $530000 | 0.0% | 27.8% | — | — | $3M |
| Sep '24 | $194000 | -$723000 | 0.0% | -581.4% | — | — | $3M |
| Jun '24 | $0 | -$1M | — | — | — | — | $5M |
| Mar '24 | $0 | -$2M | — | — | — | — | $6M |
| Dec '23 | $0 | -$2M | — | — | — | — | $8M |
| Sep '23 | $0 | $8M | — | — | — | — | $9M |
| Jun '23 | $0 | -$4M | — | — | — | — | $6M |
| Mar '23 | $0 | -$7M | — | — | — | — | $7M |
| Dec '22 | $0 | -$7M | — | — | -$7M | — | $13M |
| Sep '22 | $0 | -$10M | — | — | — | — | $20M |
| Jun '22 | $306000 | -$13M | 0.0% | -4389.9% | — | — | $30M |
| Mar '22 | $711000 | -$13M | 0.0% | -1826.2% | — | — | $41M |
| Dec '21 | $533000 | -$11M | 0.0% | -2690.1% | -$9M | — | $54M |
| Sep '21 | $348000 | -$11M | 0.0% | -3242.8% | — | — | $63M |
| Jun '21 | $3M | -$16M | 0.0% | -539.2% | — | — | $70M |
Valuation over time
How the market has priced CYCN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 6.2× (Mar '23) to 6.7× (Jun '26).
P/S
Frequently asked questions
Is CYCN growing its revenue and profit?
Over the past 5 years, Cyclerion Therapeutics, Inc.'s revenue has declined 2.0% per year. These are computed facts, not advice.
How much debt does CYCN have?
As of FY2025, Cyclerion Therapeutics, Inc. reported — of total debt against $3M of cash.
What is CYCN's profit margin?
In FY2025, gross margin was —, operating margin -239.8%, and net margin -170.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.